Week in Review: October 21–25

PubMed launches Commons; measuring HIV’s latent reservoir; immune-related pathway variation in genome, microbiome; rapamycin and flu vaccines; grasshopper mice resistant to pain

Written byTracy Vence
| 4 min read

Register for free to listen to this article
Listen with Speechify
0:00
4:00
Share

FLICKR, JJACKOWSKIIn a push for more active reader engagement after new studies are published, the newly launched PubMed Commons invites National Institutes of Health and Wellcome Trust grantees and their colleagues to begin commenting on papers indexed by the National Center for Biotechnology Information (NCBI) research database.

An organized post-publication peer review system could help “clarify experiments, suggest avenues for follow-up work and even catch errors,” Stanford University’s Rob Tibshirani, one of a team of scientists behind the development of PubMed Commons, told The Scientist. If used by a critical mass of scientists, he added, “it could strengthen the scientific process.”

The Commons was launched on Tuesday (October 22), and on Wednesday, NCBI presented step-by-step instructions on how join the resource to comment on PubMed articles. The agency is soliciting user comments during its pilot phase in order to improve the system before deciding whether to open it up to more scientists.

FLICKR, NIAIDKnowing the size of the latent reservoir (LR)—the amount of dormant DNA able to make functional virus—is essential for designing anti-HIV therapies. According to the results of PCR-based tests published in Cell this week (October 24), the HIV LR persisting in CD4+ T cells is potentially 60 times larger than previously believed.

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to more than 35 years of archives, as well as TS Digest, digital editions of The Scientist, feature stories, and much more!
Already a member? Login Here
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies